In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same:
- Prosigna can be used before the decision on adjuvant chemotherapy in women with breast cancer when there is uncertainty about the benefit of treatment;
- OncotypeDX can be used before the decision on adjuvant chemotherapy in women with breast cancer when there is uncertainty about the benefit of treatment provided that handling of personal data can take place in accordance with current Swedish and EU legislation;
- Currently, refrain from using the EndoPredict and MammaPrint due to lack of requested documentation.
The changes were only concerned with the clarification of some facts.
See the full details here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).